quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·2d
PRRelease
Cumberland Pharmaceuticals Inc. logo
Redhill Biopharma Ltd. logo

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

CPIX· Cumberland Pharmaceuticals Inc.RDHL· Redhill Biopharma Ltd.
Health Care
Original source

Companies

  • CPIX
    Cumberland Pharmaceuticals Inc.
    Health Care
  • RDHL
    Redhill Biopharma Ltd.
    Health Care

Recent analyst ratings

  • Sep 15RDHLUpdateHC Wainwright & Co.$21.00
  • Aug 31RDHLUpdateCantor Fitzgerald$22.00

Related

  • SEC1d
    SEC Form DEFA14A filed by Cumberland Pharmaceuticals Inc.
  • SEC1d
    Cumberland Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR1d
    Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
  • INSIDER1d
    SEC Form 4 filed by Raday Gilead
  • SEC2d
    SEC Form 6-K filed by Redhill Biopharma Ltd.
  • PR8d
    CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
  • SEC10d
    SEC Form 6-K filed by Redhill Biopharma Ltd.
  • INSIDER34d
    SEC Form 4 filed by Brown Martin S Jr
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022